MYDRIACYL ® (tropicamide ophthalmic solution, USP)

Manufacturer
Alcon Laboratories, Inc. | Alcon Research LLC | CARBOGEN AMCIS AG
Effective date
2022-12-22
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
11
Source
full-release
Hydrated at
2026-05-31 20:45:47

Label at a glance#

ProductMydriacyl
Active ingredientTROPICAMIDE
Label structure11 sections

Indications and uses

For mydriasis and cycloplegia for diagnostic procedures.

Dosage and administration

For refraction, instill one or two drops of 1% solution in the eye(s), repeated in five minutes. If patient is not seen within 20 to 30 minutes, an additional drop may be instilled to prolong mydriatic effect. For examination of fundus, instill one or two drops of 0.5% solution 15 or 20 minutes prior to examination. Individuals with heavily pigmented irides may require higher strength or more doses. Mydriasis will...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

MYDRIACYL® (tropicamide ophthalmic solution, USP) is an anticholinergic prepared as a sterile topical ophthalmic solution in two strengths. The active ingredient is represented by the chemical structure:

chemical
chemical

Each mL of MYDRIACYL® (tropicamide ophthalmic solution, USP) contains: Active: tropicamide 0.5% or 1%. Preservative: benzalkonium chloride 0.01%. Inactives: sodium chloride, edetate disodium, hydrochloric acid and/or sodium hydroxide (to adjust pH), purified water; pH range 4.0-5.8.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

This anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the ciliary muscle to cholinergic stimulation, dilating the pupil (mydriasis). The stronger preparation (1%) also paralyzes accommodation. This preparation acts in 15-30 minutes, and the duration of activity is approximately 3-8 hours. Complete recovery from mydriasis in some individuals may require 24 hours. The weaker strength may be useful in producing mydriasis with only slight cycloplegia. Heavily pigmented irides may require more doses than lightly pigmented irides.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

For mydriasis and cycloplegia for diagnostic procedures.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Contraindicated in persons showing hypersensitivity to any component of this preparation.

WARNINGS

WARNINGS SECTION

FOR TOPICAL OPHTHALMIC USE ONLY. NOT FOR INJECTION.

This preparation may cause CNS disturbances which may be dangerous in pediatric patients. The possibility of psychotic reactions and behavioral disturbances due to hypersensitivity to anticholinergic drugs should be considered.

Mydriatics may produce a transient elevation of intraocular pressure.

Remove contact lenses before using.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

The lacrimal sac should be compressed by digital pressure for two to three minutes after instillation to reduce excessive systemic absorption.

Information for Patients

INFORMATION FOR PATIENTS SECTION

Do not touch dropper tip to any surface, as this may contaminate the solution. Patient should be advised not to drive or engage in potentially hazardous activities while pupils are dilated. Patient may experience sensitivity to light and should protect eyes in bright illumination during dilation. Parents should be warned not to get this preparation in their child's mouth and to wash their own hands and the child's hands following administration.

Drug Interactions

DRUG INTERACTIONS SECTION

Tropicamide may interfere with the antihypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

There have been no long-term studies done using tropicamide in animals to evaluate carcinogenic potential.

Pregnancy

PREGNANCY SECTION

Animal reproduction studies have not been conducted with tropicamide. It is also not known whether tropicamide can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Tropicamide should be given to a pregnant woman only if clearly needed.

Nursing Mothers

LACTATION SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when tropicamide is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Tropicamide may rarely cause CNS disturbances which may be dangerous in pediatric patients. Psychotic reactions, behavioral disturbances, and vasomotor or cardiorespiratory collapse in children have been reported with the use of anticholinergic drugs (see WARNINGS). Keep this and all medications out of the reach of children.

Geriatric Use

GERIATRIC USE SECTION

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Ocular: Transient stinging, blurred vision, photophobia and superficial punctate keratitis have been reported with the use of tropicamide. Increased intraocular pressure has been reported following the use of mydriatics.

Non-Ocular: Dryness of the mouth, tachycardia, headache, allergic reactions, nausea, vomiting, pallor, central nervous system disturbances and muscle rigidity have been reported with the use of tropicamide. Psychotic reactions, behavioral disturbances, and vasomotor or cardiorespiratory collapse in children have been reported with the use of anticholinergic drugs.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

For refraction, instill one or two drops of 1% solution in the eye(s), repeated in five minutes. If patient is not seen within 20 to 30 minutes, an additional drop may be instilled to prolong mydriatic effect. For examination of fundus, instill one or two drops of 0.5% solution 15 or 20 minutes prior to examination. Individuals with heavily pigmented irides may require higher strength or more doses. Mydriasis will reverse spontaneously with time, typically in 4 to 8 hours. However, in some cases, complete recovery may take up to 24 hours.

HOW SUPPLIED

HOW SUPPLIED SECTION

3 mL and 15 mL in plastic DROP-TAINER® dispensers.

0.5%          15 mL: NDC 0998-0354-15

1%          3 mL: NDC 0065-0355-03

15 mL: NDC 0998-0355-15

STORAGE: Store at 8°C to 27°C (46°F-80°F). Do not refrigerate or store at high temperatures. Keep container tightly closed.


Rx Only

SPL UNCLASSIFIED SECTION

© 2004, 2018 Novartis


Distributed by:

ALCON LABORATORIES, INC.

Fort Worth, Texas 76134


Alcon®
A Novartis company
T2018-39


Revised: April 2018

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0065-0355-03

ALCON®

DROP-TAINER® DISPENSER

UNIT OF USE

Mydriacyl® 1 %
(tropicamide ophthalmic solution, USP)

3 mL Sterile

INGREDIENTS: Each mL contains:
Active:
Tropicamide 1%.
Preservative: benzalkonium chloride 0.01%.
Inactives: sodium chloride, edetate disodium, hydrochloric acid and/or sodium hydroxide (to adjust pH), purified water.
pH range 4.0-5.8

Rx Only

USUAL DOSAGE:
One or two drops topically in the eye(s). Read enclosed insert.

STORAGE:
Store at 8°-27°C (46°-80°F).

Do not refrigerate or store at high temperatures.
Keep container tightly closed.

© 2004, 2010 Alcon, Inc.

Alcon®

ALCON LABORATORIES, INC.
Fort Worth, Texas 76134 USA
Printed in USA

350544-0210

LOT:

EXP.:

carton
carton

NDC 0065-0355-03

ALCON®

Mydriacyl®
(tropicamide ophthalmic solution USP)

1 %

3 mL Sterile

Rx Only

INGREDIENTS: Each mL contains: Active: Tropicamide 1%.

USUAL DOSAGE: One or two drops topically in the eye(s). Read enclosed insert.

STORAGE:
Store at 8°-27°C (46°-80°F).
Do not refrigerate or store at high temperatures.
Keep container tightly closed.

© 2000, 2004 Alcon, Inc.

ALCON LABORATORIES, INC.
Fort Worth, Texas 76134 USA
Printed in USA

H13299-0214

LOT:

EXP.:

label
label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
208660Mydriacyl 1 % Ophthalmic SolutionPSN11
314238tropicamide 1 % Ophthalmic SolutionPSN11
208660tropicamide 10 MG/ML Ophthalmic Solution [Mydriacyl]SBD11
314238tropicamide 10 MG/ML Ophthalmic SolutionSCD11
208660Mydriacyl 1 % Ophthalmic SolutionSY11
208660Mydriacyl 10 MG/ML Ophthalmic SolutionSY11
314238tropicamide 1 % Ophthalmic SolutionSY11

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
TROPICAMIDE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
0f7ae452-206d-4fc4-868d-56fc47074084Product name120231011
6e36a95f-fcff-e2d1-3f9b-17d0b7f9e28cProduct name220200603
41722ce4-2429-80d8-5977-d735f8eca6d6Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0065-0355-03Mydriacyl1 in 1 CARTONSOLUTION/ DROPS111
0065-0355-03Mydriacyl3 mL in 1 BOTTLESOLUTION/ DROPS311

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0065-0355MYDRIACYL (TROPICAMIDE) SOLUTION/ DROPS [ALCON LABORATORIES, INC.]11Legacy NDC, 2 package rows20221224_57165763-29dc-4812-b840-a8a5086416f3.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0065-0355-03ML - Milliliter0065-03555320bac9-8845-4dbb-a1fa-6b0a0df388b512012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
TROPICAMIDEACTIVE INGREDIENTN0A3Z5XTC62
TROPICAMIDEACTIVE MOIETYN0A3Z5XTC62
BENZALKONIUM CHLORIDEINACTIVE INGREDIENTF5UM2KM3W72
EDETATE DISODIUMINACTIVE INGREDIENT7FLD91C86K2
HYDROCHLORIC ACIDINACTIVE INGREDIENTQTT17582CB2
SODIUM CHLORIDEINACTIVE INGREDIENT451W47IQ8X2
SODIUM HYDROXIDEINACTIVE INGREDIENT55X04QC32I2
WATERINACTIVE INGREDIENT059QF0KO0R2

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 8 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0065-03550065-0355-03

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 7 matching rows.

Source Document#

Source XML · Source PDF

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 10 · 557 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KINJECTION / SUBCUTANEOUS6 mgExact identifier — unii candidate
77 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRADERMALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBPOWDER / INTRAVENOUSADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBMUCOSAL16 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBSOLUTION / DENTALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAMUSCULAR1486 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / SUBARACHNOIDADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBSOLUTION / TOPICALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IENEMA / RECTAL0.44 %v/vExact identifier — unii candidate
174 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSOLUTION / ORAL432 mgExact identifier — unii candidate
77 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / INTRAVESICAL157 mgExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSOLUTION / INTRAOCULAR320 mgExact identifier — unii candidate
134 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, FOR SOLUTION / INTRATUMORADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION/ DROPS / AURICULAR (OTIC)ADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBSPRAY, METERED / NASALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICAPSULE / ORAL60 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ILOTION / TOPICAL21 mgExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBTABLET, FILM COATED / ORALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBAEROSOL, SPRAY / RESPIRATORY (INHALATION)1.5 %w/wExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XPOWDER, FOR SOLUTION / OPHTHALMIC0.9 %w/wExact identifier — unii candidate
134 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / PERINEURALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ITABLET, ORALLY DISINTEGRATING / ORAL1 mgExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / SUBCUTANEOUS1037 mgExact identifier — unii candidate
148 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / INFILTRATION0.37 %w/vExact identifier — unii candidate
148 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KINJECTION / INFILTRATION6 mgExact identifier — unii candidate
77 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IFILM, EXTENDED RELEASE / TRANSDERMAL0.85 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSOLUTION / INTRAVENOUS90 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / INTRAVENOUS2.78 %w/vExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, SUSPENSION / INTRA-ARTICULARADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / AURICULAR (OTIC)0.8 %w/wExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION / INTRA-ARTERIAL278 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRAVENOUS456 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISWAB / TOPICAL0.01 %w/wExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISPRAY / NASALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, POWDER, FOR SUSPENSION / INTRA-ARTICULAR45 mgExact identifier — unii candidate
134 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KLIQUID / INTRAVENOUS0.03 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XPOWDER, DENTIFRICE / DENTAL0.03 mg/mgExact identifier — unii candidate
134 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRACAUDALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KINJECTION, SOLUTION / INTRAMUSCULAR4 mgExact identifier — unii candidate
77 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBPOWDER, FOR SUSPENSION / ENDOTRACHEALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICAPSULE, LIQUID FILLED / ORAL1.5 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION/ DROPS / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / EXTRACORPOREALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRAMUSCULAR176 mgExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBSOLUTION / IRRIGATIONADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBSUSPENSION/ DROPS / TOPICALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRA-AMNIOTICADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XDROPS / NASALNAExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SUSPENSION / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRAPLEURALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION / INTRAVITREAL10 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICAPSULE, DELAYED RELEASE / ORAL0.25 mgExact identifier — unii candidate
174 equally ranked IID candidates
BENZALKONIUM CHLORIDEBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION / OPHTHALMIC2 %w/vExact identifier — unii candidate
24 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION / INTRAMUSCULAR1486 mgExact identifier — unii candidate
134 equally ranked IID candidates
BENZALKONIUM CHLORIDEBENZALKONIUM CHLORIDEF5UM2KM3W7SPRAY / NASAL1 mgExact identifier — unii candidate
24 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KINJECTION / INTRAVENOUS10 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSOLUTION / EPIDURAL0.9 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRAVESICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / INTRALESIONALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / INTERSTITIALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A084306-001MYDRIACYLTROPICAMIDE1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 1982

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A084306-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 1982d4dbc9d85df4…
2026-10-15 13:18:302026-09A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 1982c2088c7a36db…
2026-09-14 22:38:342026-08A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 198284e616aacf4f…
2026-08-18 06:07:402026-07A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 1982caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 1982011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 198231067a03dcf5…
2025-08-23 18:47 UTC2025-08A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 19826a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 1982fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 1982b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 198203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 19822680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 19825bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 1982d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 1982d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 198279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 1982301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 19821e350fbaab3a…
2024-05-31 18:47 UTC2024-05A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 19828072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 19825c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 19825d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 19824b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRS, Approved before 198274a2ff9319b5…
2022-03-09 01:35 UTC2022-03A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 1982bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 1982782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRS, Approved before 198287673890dc5c…
2021-03-12 10:30 UTC2021-03A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRS, Approved before 19825aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRS, Approved before 19828869cabd3fbd…
2020-11-12 02:37 UTC2020-11A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRS, Approved before 1982c0c555d07b60…
2019-12-14 00:12 UTC2019-12A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRS, Approved before 19823f01610625f2…
2019-09-15 20:21 UTC2019-09A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRS, Approved before 1982b00525d2431f…
2019-07-19 19:46 UTC2019-07A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRS, Approved before 1982ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 19826a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 19821c564ffb4f44…
2023-12-20 04:57 UTC2023-12A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 1982ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 1982a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 19829b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 1982a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 19823f0d92c62455…
2023-05-13 08:27 UTC2023-05A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 1982053a50430f4f…
2023-01-26 05:58 UTC2023-01A084306-001MYDRIACYL1%SOLUTION/DROPS / OPHTHALMICATRLD, RS, Approved before 19823bdfa0b2c4d7…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10A084306-001AT1d4dbc9d85df4…
2026-10-15 13:18:302026-09A084306-001AT1c2088c7a36db…
2026-09-14 22:38:342026-08A084306-001AT184e616aacf4f…
2026-08-18 06:07:402026-07A084306-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A084306-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A084306-001AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A084306-001AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A084306-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A084306-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A084306-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A084306-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A084306-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A084306-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A084306-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A084306-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A084306-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A084306-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A084306-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A084306-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A084306-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A084306-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A084306-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A084306-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A084306-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A084306-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A084306-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A084306-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A084306-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A084306-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A084306-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A084306-001AT1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A084306-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A084306-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A084306-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A084306-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A084306-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A084306-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A084306-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05A084306-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A084306-001AT13bdfa0b2c4d7…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
3dd122a9-260c-4d25-9f18-38373ce1b07d57165763-29dc-4812-b840-a8a5086416f32022-12-22Warnings, Adverse reactionsExact identifier
spl id: 3dd122a9-260c-4d25-9f18-38373ce1b07d
spl set id: 57165763-29dc-4812-b840-a8a5086416f3

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.